Skip to main content
NIBEC CO., LTD. logo

NIBEC CO., LTD. — Investor Relations & Filings

Ticker · 138610 ISIN · KR7138610001 KO Manufacturing
Open in API
Filings indexed 218 across all filing types
Latest filing 2025-03-10 AGM Information
Country KR South Korea
Listing KO 138610

About NIBEC CO., LTD.

https://nibec.co.kr/en/

NIBEC CO., LTD. is a biotechnology company specializing in the research, development, and commercialization of healthcare solutions centered on proprietary peptide technology. The company's core activities involve the manufacturing of tissue regenerative biomaterials, such as dental bone grafts and collagen-based products, as well as biomaterial-based medical devices. In addition to its focus on regenerative medicine, NIBEC develops and markets a range of dental care and cosmetic products. The company is also actively engaged in the research and development of novel peptide-based drugs and bio-fusion technologies to address various therapeutic needs.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal notification filed by the company (Naibec) to the regulatory body (KRX) explaining the reason for holding their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). This is a specific regulatory disclosure requirement in the Korean market regarding AGM scheduling. Since it is a regulatory announcement regarding the meeting logistics rather than the meeting materials themselves or the voting results, it falls under the general regulatory filing category.
2025-03-10 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding the acquisition of convertible bonds before maturity (early redemption). It details the specific bond series (8th series), the acquisition amount, the reason (exercise of put option by bondholders), and the method of disposal (cancellation). This falls under capital structure changes and financing updates related to debt instruments.
2025-02-24 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement from the company '나이벡' regarding the setting of a record date for the purpose of determining shareholders eligible to attend the 21st Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the record date for the upcoming meeting. This fits the definition of a general regulatory announcement regarding corporate actions.
2024-12-16 Korean
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the company 'NIBEC' regarding the adjustment of the conversion price of convertible bonds due to a decline in market price. This type of disclosure, which details changes to capital structure instruments like convertible bonds, falls under the category of 'Capital/Financing Update' (CAP) as it directly relates to the company's financing activities and capital structure adjustments.
2024-11-22 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '주식회사 나이벡' (NIBEC Co., Ltd.) covering the period from 2024-01-01 to 2024-09-30. It contains detailed financial information, business descriptions, and management reports, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-13 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (나이벡 펩타이드 기반 염증성장질환치료제(NIPEP-IBD, 코드명 NP-201) 호주 임상 1b/2a 임상 시험계획 승인)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure from a Korean company (NIBEC) regarding the approval of a clinical trial (Phase 1b/2a) for a drug candidate. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filings on the Korea Exchange (KRX). Since it is a specific regulatory announcement regarding clinical trial status and does not fit into categories like financial reports, dividends, or M&A, it is classified as a Regulatory Filing (RNS).
2024-11-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.